During the past decade, Shanghai First People's Hospital conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 16 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 7 clinical trials were completed. i.e. 53.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai First People's Hospital" #1 sponsor was "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine" with 9 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Shanghai Jiao Tong University School of Medicine" with 7 trials sponsored, "Chengdu Kanghong Biotech Co., Ltd." with 6 trials sponsored and "Beijing Friendship Hospital" with 6 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai First People's Hospital" #1 collaborator was "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine" with 9 trials as a collaborator, "Shanghai Zhongshan Hospital" with 7 trials as a collaborator, "Tongji Hospital" with 7 trials as a collaborator, "Huashan Hospital" with 5 trials as a collaborator and "Beijing Tiantan Hospital" with 4 trials as a collaborator. Other collaborators include 195 different institutions and companies that were collaborators in the rest 122 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai First People's Hospital" are "Liver Transplantation" (5 trials), "Neovascular Age-related Macular Degeneration" (4 trials), "Coronary Artery Disease" (3 trials), "Diabetic Macular Edema" (3 trials) and "Asthma" (2 trials). Many other conditions were trialed in "Shanghai First People's Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai First People's Hospital" are "Drug" (61 trials), "Device" (11 trials), "Procedure" (9 trials), "Biological" (6 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Sham Procedure" (5 trials), "Aflibercept" (4 trials), "Faricimab" (4 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai First People's Hospital" are 79 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Shanghai First People's Hospital". 1 are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Shanghai First People's Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai First People's Hospital, 4 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 22 trials, and there were also 15 trials that are defined as “Not Applicable".